US pharma giant Pfizer (NYSE: PFE) has published a new interim analysis of long-term data from four studies of its rare disease therapy Vyndaqel (tafamidis).
Published in the journal Amyloid, the analysis shows the drug is associated with delay in disease progression in patients with hereditary transthyretin amyloid polyneuropathy (TTR-FAP).
The analysis, which included patients with the most common TTR-FAP mutation, Val30Met, showed the drug was well tolerated, with no unexpected side effects.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze